ACM
ABBV icon

Ascent Capital Management’s AbbVie ABBV Stock Holding History

Ascent Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$261K Buy
+1,127
New +$230K 0.21% 47
2025
Q2 		– Sell
-1,132
Closed -$237K – 63
2025
Q1 		$237K Buy
+1,132
New +$220K 0.24% 49

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ascent Capital Management's ABBV Position: Q3 2025 in Review

Ascent Capital Management opened a new position in AbbVie (ABBV) in Q3 2025: 1,127 shares worth $261K. The stake represents 0.21% of the portfolio and ranks #47 among its holdings. This is a return to the name: Ascent Capital Management previously reported a position in ABBV as recently as Q1 2025.

Ascent Capital Management first reported a position in ABBV in Q1 2025 and has held it in 2 quarters since. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Ascent Capital Management held 1,127 shares of AbbVie worth $261K as of Q3 2025.
  • AbbVie was a new Ascent Capital Management position in Q3 2025.
  • AbbVie made up 0.21% of Ascent Capital Management's portfolio in Q3 2025, its #47 holding.
  • Ascent Capital Management first reported a position in AbbVie in Q1 2025 and has held it in 2 quarters since.
  • 3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Ascent Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.